-
-
-
-
-
-
-
Clearmind reports improved nasal retention for its MEAI drug formulation
-
-
-
-
-
-
-
Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI
-
-
-
-
-
-
-
Clearmind Medicine completes Part A dosing in Phase I/II alcohol disorder trial
-
-
-
-
-
-
-
Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts
-
-
-
-
-
-
-
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder
-
-
-
-
-
-
-
Clearmind Medicine Welcomes President Trump’s Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care
-
-
-
-
-
-
-
Clearmind Medicine completes treatment for 18 participants in phase 1 trial
-
1,172,172 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

